



Concentration you can count on

Restigen® PRP provides reliable output with up to 9x platelet concentration, ensuring minimal variability for effective soft tissue healing.¹⁻⁴




Restigen®
PRP




What is Restigen PRP?

It's a one-step device that creates a concentrated platelet-rich plasma (PRP) solution from a horse's own blood to primarily help the body repair a wide range of soft tissue injuries. PRP can also be used in joint injuries causing lameness.¹⁻⁴




All three components (plasma, platelets and white blood cells) are optimal for natural healing, repair and regeneration of soft and hard tissues like tendons, ligaments, muscles and bones.^{3,4}


How Restigen helps repair soft tissue



Soft tissue injury occurs when tendon fibers are stretched and torn, producing heat, pain and swelling that results in lameness.



When injected into the injured area, Restigen PRP provides highly concentrated platelets, growth factors, white blood cells and anti-inflammatory cytokines to help enable healing with reduced scar tissue.



PRP enables improved quality of tendon fiber regeneration during the healing process.^{5,6}

Why choose Restigen

It is a clinically studied, evidence-backed PRP device trusted by professionals and delivers up to 90% platelet recovery at 9x concentration, providing consistent, high-quality results.⁴

SAFE FOR THE HORSE



All natural, from your own horse



No foreign body response



No concern for repeat injections



May be used for a range of problems



Demonstrated effectiveness^{3,4}

Restigen is the most trusted equine orthobiologic in cases of soft tissue injury:⁷

✓ Tendon

✓ Ligament

CONVENIENT FOR YOU



Improvement after one injection⁸



Portable and stall-side



Fast processing in less than 15 minutes



Ability to use platelet-poor plasma (PPP)



Scan to learn more about our Regenerative Medicine Device portfolio.

[ZoetisEquine.com/Lameness](https://zoetisequine.com/Lameness)

Comparative analysis of commercially available PRPs

Category of lameness treatment	Brand name	Platelet concentration	Concern for repeat injections	Ability to utilize PPP	Anti-inflammatory proteins	White blood cells	Growth factors	Validated in equine blood	Concentrates IRAP
PRP: Platelet-rich plasma	Restigen® PRP	7-9X	No	✓	✓	✓	✓	✓ ¹⁰	✓ ¹⁰
	ProVet® APC	7X	No	✗	✓	✓	✓	✓	✓
	Arthrex® APC (60mL)	5X ⁹	No	✓	✓	Reduced ⁹	✓	✓ ⁹	Below the level of detection ¹⁰
	Precise® PRP™	4 billion plts/vial	Possible due to universal donor pool	✗	✓	✗	✓	✗	No publications

Knowing the difference



Restigen® PRP

Soft tissue application
Up to 9x Concentration⁴



Pro-Stride® APS

Intra-articular application
Highly concentrated
M1 to M2 monocyte shift



What equine veterinarians are saying about Restigen⁵



Restigen ranked first by veterinarians among equine PRPs in:

PRP I trust

Consistent and predictable outcomes

Duration of effect

Supported by equine-specific science and research^{8,11-15}

Safety for the horse

Preferred onset of results

HEALING WITH HORSE POWER

REGENERATIVE MEDICINE DEVICES



Pro-Stride[®]
APS

**One-of-a-kind healing
power backed by
industry-leading research.**



CentRate[®]
BMA

**Unlock advanced
stall-side healing with
the power of stem cells.**



Scan to learn more about our Regenerative Medicine Device portfolio.
ZoetisEquine.com/Lameness

Visit ZoetisEquine.com for more information and follow us on social media for updates.



@ZoetisEquine



@zoetisequine



Zoetis Equine

zoetis

References

1. Data on file: TI-06310 – Additional Study No. OT000183 Validation.
2. Bosch et al. Computerised analysis of standardised ultrasonographic images to monitor the repair of surgically created core lesions in equine superficial digital flexor tendons following treatment with intratendinous platelet rich plasma or placebo. *The Veterinary Journal* 187 (2011) 92–98.
3. Chahla et al. A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. *J Bone Joint Surg Am.* 2017 Oct 18;99(20):1769–1779.
4. Veloso Alvarez et al. A survey of clinical usage of non-steroidal intra-articular therapeutics by equine practitioners. *Front Vet Sci.* Oct. 2020. Article 579967.
5. Bosch, G., Moleman, M., Barneveld, A., van Weeren, P. R., & van Schie, H. T. M. (2011). The effect of platelet-rich plasma on the neovascularization of surgically created superficial digital flexor tendon lesions in horses. *Scandinavian Journal of Medicine & Science in Sports*, 21(4), 554–561; DOI: 0.1111/j.1600-0838.2009.01070.x
6. Bosch, G., van Schie, H. T. M., de Groot, M. W., Cadby, J. A., van de Lest, C. H. A., Barneveld, A., & van Weeren, P. R. (2010). Effects of platelet-rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: a placebo-controlled experimental study. *Journal of Orthopaedic Research*, 28(2), 211–217. DOI: 10.1002/jor.20980
7. Data on file. Equine orthobiologics Market Research Study Parts 1-4 US Market Research Dept. Jun 27 2025.
8. Bertone et al. Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses. *Am J Vet Res* 2014, 75(2): 141-151. DOI: 10.2460/ajvr.75.2.141
9. <https://www.arthrex.com/resources/LAI-000146-en-US/comparison-of-the-arthrex-acp-double-syringe-system-and-regenkit-prgen-lab>
10. Barot D, Usimaki A, Linardi R et al. Equine autologous blood-based products contain variable quantities of transforming growth factor-β1, interleukin-1 receptor agonist, and α2-macroglobulin. *AJVR.* Jan 30, 2025. DOI: <https://doi.org/10.2460/ajvr.24.11.0363>
11. Page, A.E.; Johnson, M.; Parker, J.L.; Jacob, O.; Poston, R.; Adams, A.A.; Adam, E.N. The Effects of Intra-Articular Triamcinolone and Autologous Protein Solution on Metabolic Parameters in Horses. *Animals* 2024, 14, 2250. <https://doi.org/10.3390/ani14152250>
12. Rowland AL, Miller D, Berglund A, Schnabel LV, Levine GJ, Antczak DF, Watts AE. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting. *Stem Cells Transl Med.* 2021 May;10(5):694-710. doi:10.1002/sctm.20-0435
13. Usimaki A, Ciamillo SA, Barot D, et al. Single injection of intra-articular autologous protein solution in horses with acute interleukin-1β-induced synovitis decreases joint pathology scores. *Equine Vet J.* 2024; 1-11. <https://doi.org/10.1111/evj.14203>
14. Moorman, V. J., Hart, K. A., Gordon, J., Page, A. E., & Adams, A. A. (2024). Cytokine Profiles of Autologous Conditioned Serum (ACS) and Autologous Protein Solution (APS) from horses with Pituitary Pars Intermedia Dysfunction (PPID) and Unaffected Controls. *VCOT Open.* <https://doi.org/10.1055/s-0044-1786215>
15. Brown KA, Gregorio E, Barot D, et al. Single-dose nonsteroidal anti-inflammatory drugs in horses have no impact on concentrations of cytokines or growth factors in autologous protein solution and platelet-rich plasma. *AJVR*, Feb 15, 2024. <http://doi.org/10.2460/ajvr.23.11.0258>

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2026 Zoetis Services LLC. All rights reserved. RES-00010